GLP1R and Obesity: It is simultaneously true that with obesity disproportionately affecting lower socioeconomic populations [163], designating weight loss as an off-label indication for GLP-1 RAs could be tantamount to financial gatekeeping, potentially further entrenching health inequities within these populations.